Targovax ASA - ESG Rating & Company Profile powered by AI
If you are employed by Targovax ASA and you wish to licence your Sustainability rating, please contact us. This page contains a zero-cost E,S&G report covering Targovax ASA. The Sustainability assessment for Targovax ASA indicates the company's reporting of the United Nations Sustainable Development Goals.
Targovax ASA in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.2; made up of an environmental score of 2.0, social score of 8.0 and governance score of 5.7.
5.2
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 912 | Vivanza Biosciences Ltd | 5.3 | High |
| 912 | ValiRx PLC | 5.3 | High |
| 958 | Targovax ASA | 5.2 | High |
| 958 | Altimmune Inc | 5.2 | High |
| 958 | Agios Pharmaceuticals Inc | 5.2 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Targovax ASA have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Targovax ASA disclose current and historical energy intensity?
Sign up for free to unlockDoes Targovax ASA report the average age of the workforce?
Sign up for free to unlockDoes Targovax ASA reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Targovax ASA disclose its ethnicity pay gap?
Sign up for free to unlockDoes Targovax ASA disclose cybersecurity risks?
Sign up for free to unlockDoes Targovax ASA offer flexible work?
Sign up for free to unlockDoes Targovax ASA have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Targovax ASA disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Targovax ASA conduct supply chain audits?
Sign up for free to unlockDoes Targovax ASA disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Targovax ASA conduct 360 degree staff reviews?
Sign up for free to unlockDoes Targovax ASA disclose the individual responsible for D&I?
Sign up for free to unlockDoes Targovax ASA disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Targovax ASA disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Targovax ASA disclose water use targets?
Sign up for free to unlockDoes Targovax ASA have careers partnerships with academic institutions?
Sign up for free to unlockDid Targovax ASA have a product recall in the last two years?
Sign up for free to unlockDoes Targovax ASA disclose incidents of discrimination?
Sign up for free to unlockDoes Targovax ASA allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Targovax ASA issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Targovax ASA disclose parental leave metrics?
Sign up for free to unlockDoes Targovax ASA disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Targovax ASA disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Targovax ASA disclose the pay ratio of women to men?
Sign up for free to unlockDoes Targovax ASA support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Targovax ASA disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Targovax ASA reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Targovax ASA involved in embryonic stem cell research?
Sign up for free to unlockDoes Targovax ASA disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Targovax ASA disclose its waste policy?
Sign up for free to unlockDoes Targovax ASA report according to TCFD requirements?
Sign up for free to unlockDoes Targovax ASA disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Targovax ASA disclose energy use targets?
Sign up for free to unlockDoes Targovax ASA disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Targovax ASA have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Targovax ASA
These potential risks are based on the size, segment and geographies of the company.
Targovax ASA, a clinical stage immuno-oncology company, engages in the development of immune activators to target hard-to-treat solid tumors. Its lead product candidate is ONCOS-102, which is in Phase I/II clinical trials for the treatment of mesothelioma, melanoma, and colorectal cancer. The company is also developing neoantigen vaccines targeting mutant KRAS cancers. In addition, it is developing ONCOS-211 for next generation ONCOS viruses. The company has collaboration agreements with Cancer Research Institute and Ludwig Cancer Research to develop ONCOS-102 for colorectal cancer with peritoneal carcinomatosis; Valo Therapeutics to develop mutant RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology; and Papyrus Therapeutics to develop novel ONCOS viruses with Receptor Tyrosine Kinase inhibitor functionality. Targovax ASA was incorporated in 2010 and is based in Lysaker, Norway.